Vertex Energy

Vertex reported Q1 2026 EPS of $4.47 (estimate $4.33), beating earnings expectations, while revenue of $2.99 billion was slightly below the expected $3.03 billion. Total product revenue rose 8% year over year, driven by new products such as CASGEVY and JOURNAVX. The company has $13 billion in liquidity and provided guidance calling for expected EPS of $4.75 for Q2 2026 and $5.14 for Q1 2027; revenue for 2026 is forecast at $13.02 billion. » Más en de.investing.com

Vertex’s share hit a 52-week low of $11.86, roughly 66.6% below its value a year earlier, after a steep drop from its high of $42.44. Despite the sell-off, the company reports a gross profit margin of 64%, and a fair-value analysis points to possible undervaluation. Analysts remain divided: Goldman Sachs reaffirms buy (price target $23), while DA Davidson, Citizens and Jefferies have in part cut price targets or downgraded to hold. Additionally, Vertex has made its O Series Tax Engine and the Indirect Tax Accelerator available on the Oracle Financial Software Cloud Marketplace to automate tax processes in Oracle ERP environments. » Más en de.investing.com

Vertex reports successful phase III results for Povetacicept in IgA nephropathy: proteinuria fell by 52% versus placebo in the 36‑week study, and Gd‑IgA1 levels dropped by 77.4%. Analysts call it outstanding real‑world data and see the step as an important milestone for Vertex's expansion toward a leadership position in nephrology. The success also validates the acquisition of Alpine Immune Sciences and opens up a long‑term revenue potential of more than US$10 billion. Investors reacted with significant share gains; the stock rose sharply intraday. » Más en finanzen.net